We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

103 hedge funds and large institutions have $388M invested in BioXcel Therapeutics in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 25

3% more capital invested

Capital invested by funds: $378M → $388M (+$9.86M)

0.07% less ownership

Funds ownership: 2.93% → 2.86% (-0.07%)

4% less call options, than puts

Call options by funds: $6.54M | Put options by funds: $6.84M

5% less funds holding

Funds holding: 108 → 103 (-5)

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

Holders
103
Holders Change
-5
Holders Change %
-4.63%
% of All Funds
1.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
50
Reduced
25
Closed
17
Calls
$6.54M
Puts
$6.84M
Net Calls
-$301K
Net Calls Change
+$2.7M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.4M
2
AIM
Artemis Investment Management
United Kingdom
+$5.14M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$3.57M
4
BlackRock
BlackRock
New York
+$2.32M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$2.12M

Top Sellers

Rank Fund Capital Flow
1
AS
Altshuler Shaham
Israel
-$6.86M
2
CCM
CAAS Capital Management
New York
-$6.75M
3
GCM
Ghisallo Capital Management
Massachusetts
-$5.63M
4
LM
Luminus Management
Texas
-$4.57M
5
Blackstone Inc
Blackstone Inc
New York
-$4.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$115M +$18.4M +41,911 +22%
AIM
2
Artemis Investment Management
United Kingdom
$41.9M +$5.14M +11,685 +16%
State Street
3
State Street
Massachusetts
$40.3M -$3.59M -8,158 -9%
BlackRock
4
BlackRock
New York
$36.9M +$2.32M +5,271 +7%
AllianceBernstein
5
AllianceBernstein
Tennessee
$31M +$2.12M +4,812 +8%
Vanguard Group
6
Vanguard Group
Pennsylvania
$29.4M +$1.79M +4,080 +7%
Massachusetts Financial Services
7
Massachusetts Financial Services
Massachusetts
$12.7M +$3.57M +8,109 +45%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$9.02M +$556K +1,264 +7%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$7.26M +$677K +1,540 +11%
UBS Group
10
UBS Group
Switzerland
$6.55M +$1.51M +3,445 +34%
Northern Trust
11
Northern Trust
Illinois
$5.77M +$256K +583 +5%
Charles Schwab
12
Charles Schwab
California
$3.94M +$748K +1,701 +26%
Morgan Stanley
13
Morgan Stanley
New York
$3.66M +$40.5K +92 +1%
Bank of America
14
Bank of America
North Carolina
$1.93M -$417K -949 -19%
Rafferty Asset Management
15
Rafferty Asset Management
New York
$1.81M -$250K -568 -13%
GCP
16
GSA Capital Partners
United Kingdom
$1.8M +$1.63M +3,709 New
Bank of New York Mellon
17
Bank of New York Mellon
New York
$1.65M +$124K +282 +9%
Two Sigma Investments
18
Two Sigma Investments
New York
$1.55M -$2.19M -4,984 -61%
ACM
19
ACT Capital Management
Pennsylvania
$1.52M +$220K +500 +19%
N
20
Nuveen
North Carolina
$1.43M -$255K -580 -17%
B
21
Bailard
California
$1.4M +$1.26M +2,875 New
Swiss National Bank
22
Swiss National Bank
Switzerland
$1.29M – – –
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
23
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.21M – – –
Citigroup
24
Citigroup
New York
$1.2M -$1.79M -4,066 -62%
Two Sigma Advisers
25
Two Sigma Advisers
New York
$1.13M -$767K -1,744 -43%
1
2 3 4 5

BTAI Hedge Fund Activity: Q3 2021 in Review

103 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2021, worth a combined $388M — up 2.6% from $378M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of BTAI and 12 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 50 added.

The largest buyer was Fidelity Investments, adding an estimated $18.4M. The largest seller was Altshuler Shaham, cutting an estimated $6.86M.

  • 103 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2021, down from 108 in Q2 2021.
  • Funds reported $388M of BioXcel Therapeutics stock for Q3 2021, up 2.6% quarter-over-quarter.
  • 12 funds opened new BioXcel Therapeutics positions in Q3 2021 and 17 closed out, a net change of -5 holders.
  • The largest BioXcel Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $18.4M added.
  • The largest BioXcel Therapeutics seller in Q3 2021 was Altshuler Shaham, an estimated $6.86M sold.

Based on aggregated 13F filings for Q3 2021.